Find a Physician | How to Contribute | About Us | Clinical Trials
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG PLX108-08

An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Principal Investigator
Jeffrey Raizer
  • Status: CLOSED
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG PLX108-08
The purpose of this research study is to assess the safety and efficacy of PLX3397 (the study drug) in people diagnosed with a type of brain cancer called gliblastoma multiforme (GBM).
This study is for patients who have been diagnosed with GMB. GBM is the most frequent type of brain tumor, accounting for about 12% to 15% of all brain tumors. In this is a study research are looking at an experimental study drug, PLX3397, for the treatment of GBM. “Experimental” means that the study drug is currently being tested and is not approved for sale in the United States by the Food and Drug Administration (FDA).
Some of the eligibility criteria include:
  • Participants must have a diagnosis of GBM or gliosarcoma.
  • Participants must have had surgery to remove all or part of the cancer within 5 weeks of starting the study.
  • Participants must be 18 or older.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
All study participants will take capsules of the study drug by mouth twice a day. After taking study drug twice a day for the first 7 days, participants will begin radiation therapy on day 8 and continue once a day 5 times per week for 6 weeks. Participants will continue to take study drug twice a day while being given radiation therapy. In addition to study drug and radiation therapy, participants will also receive another drug, Temozolomide. It is a capsule taken by mouth taken once a day for 42 days (6 weeks) beginning on day 8 (same day as beginning radiation therapy). Then, after a 28-day break, it may be taken once a day for 5 days in a row, followed by a 23-day break before repeating the next dosage cycle. The doctor will decide how many times participants should repeat the treatment cycles.
Clinical Trials Recruitment Nurse
Robert H. Lurie Comprehensive Cancer Center

Find Related Clinical Trials

Browse by Disease Sites

last updated: 20-Oct-17 03:38 AM


Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.